Secondary
Akari Therapeutics
Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression.
Symbol
AKTX
Last Closing Price
$6.40
Effective Date
October 18, 2017
Underwriters
Cantor Fitzgerald, Willaim Blair, Canaccord Genuity
To view the prospectus for Akari Therapeutics, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277